FIGURE 6.

Effect of Nanobodies on cell cycle progression of cancer cells and release of angiogenic factors. A, cell cycle analysis of 22A cells in the absence or presence of CXCR7 (CXCL12 or NB4) or EGFR (EGF ligand or EGFR-specific monoclonal antibody Erbitux) reagents. B, secretion of angiogenic factors from 22A cells in the absence or presence of NB4 (10⁻⁶ m). Only CXCL1–3, CCL5, angiogenin CXCL8, and TIMP1 were detected in this array and were, therefore, quantified (p < 0.05 in an unpaired t test comparison). C, validation of angiogenesis array by the use of ELISA. Secretion of CCL5, CXCL1, and CXCL2 was measured in 22A cells in the absence or presence of NB4 (10⁻⁶ m) for 72 h. n.s., not significant. *, p < 0.05, **, p < 0.01 in unpaired t test treated versus control cells.